Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

HDAC inhibitors potentiate the efficacy of antineoplastic agents in acute megakaryoblastic leukemia via dual activation of apoptosis and pyroptosis

View Full Paper
Ask AI
Bookmark
Share

Authors

HLHu Liu

Discussion

Loading...

Member takes

Overview

This analysis reveals enhanced cell death via HDAC inhibitors in acute megakaryoblastic leukemia, indicating potential for combination therapy.

Key Points

  • HDAC inhibitors induce apoptosis and pyroptosis in acute megakaryoblastic leukemia models, promoting effective cell death.
  • Caspase-9 was identified as a critical pathway mediator in HDAC-dependent cell death mechanisms.
  • Treatment combining HDAC inhibitors and BCL-XL inhibitors significantly reduces tumor burden in pediatric acute megakaryoblastic leukemia models, improving survival rates.
  • This multimodal approach highlights the potential for innovative therapies against aggressive pediatric leukemias.

Cite This Study

Hu Liu (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d4bahttps://doi.org/10.1182/blood-2025-3243
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effects of BCL-2 and MCL-1 Inhibition on Apoptotic and Transcriptional Profiles in Acute Myeloid Leukemia2026
  2. 2Chidamide reprograms AML-associated macrophages via HDAC3 inhibition to boost CD8+ T cell immunity2025
  3. 3Clinicopathological characteristics and survival outcomes in adults with acute megakaryoblastic leukemia2025
  4. 4Targeted Degradation of Class 1 HDACs With PROTACs is Highly Effective at Inducing DLBCL Cell Death2025 · 4 citations
  5. 5Investigating KAT2A protac therapy for targeting leukemic blast differentiation in acute myeloid leukaemia.2025